Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

444 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting.
Bettelli S, Marcheselli R, Pozzi S, Marcheselli L, Papotti R, Forti E, Cox MCC, Di Napoli A, Tadmor T, Mansueto GR, Musto P, Flenghi L, Quintini M, Galimberti S, Lalinga V, Donati V, Maiorana A, Polliack A, Sacchi S. Bettelli S, et al. Among authors: galimberti s. Leuk Res. 2021 May;104:106552. doi: 10.1016/j.leukres.2021.106552. Epub 2021 Feb 27. Leuk Res. 2021. PMID: 33689920 No abstract available.
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, Di Raimondo F, Carella AM, Pulsoni A, Merli F, Arcaini L, Angrilli F, Stelitano C, Gaidano G, Dell'olio M, Marcheselli L, Franco V, Galimberti S, Sacchi S, Brugiatelli M. Federico M, et al. Among authors: galimberti s. J Clin Oncol. 2013 Apr 20;31(12):1506-13. doi: 10.1200/JCO.2012.45.0866. Epub 2013 Mar 25. J Clin Oncol. 2013. PMID: 23530110 Free article. Clinical Trial.
Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma.
Massaro F, Stepanishyna Y, Manni M, Luminari S, Galimberti S, Marcheselli L, Visco C, Tecchio C, Stelitano C, Angrilli F, Petrini M, Merli F, Federico M. Massaro F, et al. Among authors: galimberti s. Br J Haematol. 2021 Mar;192(6):1011-1014. doi: 10.1111/bjh.16714. Epub 2020 May 14. Br J Haematol. 2021. PMID: 32410259 Free article. Clinical Trial.
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.
Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, Marcheselli L, Ladetto M, Piccaluga PP, Gazzola A, Mannu C, Monitillo L, Mantoan B, Del Giudice I, Della Starza I, Cavalli M, Arcaini L, Tucci A, Palumbo GA, Rigacci L, Pulsoni A, Vitolo U, Boccomini C, Vallisa D, Bertoldero G, Gaidano G, Musto P, Petrini M, Federico M. Galimberti S, et al. Clin Cancer Res. 2014 Dec 15;20(24):6398-405. doi: 10.1158/1078-0432.CCR-14-0407. Epub 2014 Oct 14. Clin Cancer Res. 2014. PMID: 25316810 Free article.
Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma.
Alonso-Álvarez S, Manni M, Montoto S, Sarkozy C, Morschhauser F, Wondergem MJ, Guarini A, Magnano L, Alcoceba M, Chamuleau M, Galimberti S, Gomes da Silva M, Holte H, Zucca E, Lockmer S, Aurer I, Marcheselli L, Stepanishyna Y, Caballero Barrigón MD, Salles G, Federico M. Alonso-Álvarez S, et al. Among authors: galimberti s. Eur J Cancer. 2021 Nov;157:132-139. doi: 10.1016/j.ejca.2021.08.005. Epub 2021 Sep 8. Eur J Cancer. 2021. PMID: 34508995
Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.
Massaro F, Pavone V, Stefani PM, Botto B, Pulsoni A, Patti C, Cantonetti M, Visentin A, Scalzulli PR, Rossi A, Galimberti S, Cimminiello M, Gini G, Musso M, Sorio M, Arcari A, Zilioli VR, Luppi M, Mannina D, Fabbri A, Pietrantuono G, Annibali O, Tafuri A, Prete E, Mulè A, Barbolini E, Marcheselli L, Luminari S, Merli F. Massaro F, et al. Among authors: galimberti s. Hematol Oncol. 2022 Feb;40(1):31-39. doi: 10.1002/hon.2939. Epub 2021 Nov 1. Hematol Oncol. 2022. PMID: 34694649 Free PMC article.
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Morabito F, Gentile M, Ciolli S, Petrucci MT, Galimberti S, Mele G, Casulli AF, Mannina D, Piro E, Pinotti G, Palmieri S, Catalano L, Callea V, Offidani M, Musto P, Bringhen S, Baldini L, Tosi P, Di Raimondo F, Boccadoro M, Palumbo A, Cavo M. Morabito F, et al. Among authors: galimberti s. Eur J Haematol. 2010 Mar;84(3):223-8. doi: 10.1111/j.1600-0609.2009.01385.x. Epub 2009 Nov 23. Eur J Haematol. 2010. PMID: 19930441
Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, Stelitano C, Musso M, Baldini L, Galimberti S, Angrilli F, Polimeno G, Scalzulli PR, Ferrari A, Marcheselli L, Federico M. Merli F, et al. Among authors: galimberti s. J Clin Oncol. 2016 Apr 10;34(11):1175-81. doi: 10.1200/JCO.2015.62.4817. Epub 2015 Dec 28. J Clin Oncol. 2016. PMID: 26712220 Free article. Clinical Trial.
Myeloid neoplasms and autoimmune diseases: markers of association.
Galimberti S, Baldini C, Baratè C, Fornili M, Balducci S, Ricci F, Ferro F, Elefante E, Di Paolo A, Baglietto L, Donati V, Petrini M. Galimberti S, et al. Clin Exp Rheumatol. 2022 Jan;40(1):49-55. doi: 10.55563/clinexprheumatol/ddxmp9. Epub 2021 Jan 6. Clin Exp Rheumatol. 2022. PMID: 33427624 Free article.
444 results